20 minutes ago
Pamufetinib 50 mg and 100 mg did not slow FVC decline versus continued nintedanib or pirfenidone in progressive fibrosing ILD, a phase 2b trial found.
46 minutes ago
Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.
2 hours ago
This Q&A interview continues Gooderham's discussion of new upadacitinib treatment data on patients living with severe alopecia areata.
4 hours ago
Andrew Mastro, MS, PA-C, closes out this stretch of the conversation by asking Alexa Hetzel, MS, PA-C, to look three to five years ahead and describe how she expects the plaque psoriasis treatment paradigm to evolve.
4 hours ago
Andrew Mastro, MS, PA-C, widens the lens and asks Alexa Hetzel, MS, PA-C, where icotrokinra sits within the broader plaque psoriasis landscape, including whether route of administration itself shapes patient preference.